Market Cap 28.63M
Revenue (ttm) 0.00
Net Income (ttm) -66.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,900
Avg Vol 27,034
Day's Range N/A - N/A
Shares Out 40.85M
Stochastic %K 55%
Beta -0.43
Analysts Sell
Price Target $5.50

Company Profile

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis...

Industry: Biotechnology
Sector: Healthcare
Phone: 443 917 0966
Address:
20400 Century Boulevard, Suite 210, Germantown, United States
focafoca99
focafoca99 May. 21 at 10:15 AM
$BRNS secured shareholder approval of its Scheme of Arrangement after a 99.98% vote in favor.
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 1:40 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 13 at 10:10 PM
$BRNS Brilliant piece that captures BRNS's situation perfectly. So if you want to update your understanding of BRNS or get to know BRNS better, this is essential reading. https://everyticker.com/quote/BRNS/analysis/barinthus-bio-s-0-67-survival-bet-merger-lifeline-meets-celiac-catalyst-nasdaq-brns
0 · Reply
xElysian
xElysian May. 9 at 6:17 AM
$BRNS Barinthus is currently in the process of merging with Clywedog Therapeutics, a move expected to close in mid-2026.
0 · Reply
PenkeInvesting
PenkeInvesting May. 4 at 11:05 PM
Fundamental analysis of $BRNS (Barinthus Biotherapeutics plc.) based on financial data and reported results. #BRNS
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 16 at 3:30 PM
$VTGN Any good CEO already has a contingency plan in place in case data is not good. Most likely they are already in talks for some sort of strategic alt deal if the data is meh. $RLYB did it, $CYCN did it, $BRNS did it, $NEUP did it, all behind the scenes while waiting on data and continuing business as usual. With 60m cash on hand Dec 31, and likely 45m+ on hand today we are trading at over 1/2 cash value. Any binary announcement likely has limited downside and loads of upside. Again, no matter the result here I still think it is a asymmetrical risk/reward situation. Risk -30% to possibly gain 100%+ Do your own DD of course but I've loaded up the boat. Options: A). Data is good, stock pumps B). Data is bad, announce strat alt review , stock rebounds to near current levels C). Reverse merger deal out of nowhere, stock explodes based on cash position. Look at $RLYB $CYCN $BRNS etc. All of them happened out of nowhere.
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 13 at 9:10 PM
$BRNS RSI: 41.43, MACD: -0.0172 Vol: 0.05, MA20: 0.59, MA50: 0.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 13 at 8:14 PM
$PCSA I still maintain this is less about data and more likely a RM play, whether it be a crypto treasury RM w/ Dreyfus or some other company. I think the data continually being delayed is very telling that the company is not planning on continuing on their own. Just my opinion. $BRNS $VYNE and $RLYB all are recent examples of companies who had upcoming data but all ended up doing RM's instead.
2 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 7 at 6:19 PM
$NEUP Both the $GLTO and $BRNS CEO's sent me similiar responses and then the deal was announced with 10 days of each of them...so assuming timing is always iffy. But this is a good, solid response. Thanks for sharing.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 20 at 5:00 AM
$BRNS Q4 '25 Earnings Results & Recap Barinthus Biotherapeutics PLC expects to incur net operating losses for at least the next several years as it advances product candidates and anticipates its existing cash, cash equivalents, and restricted cash will fund operations for at least 12 months.
0 · Reply
Latest News on BRNS
Barinthus Biotherapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 22 days ago

Barinthus Biotherapeutics Proxy statement: Proxy filing


Barinthus Biotherapeutics Earnings release: Q1 2026

Apr 30, 2026, 7:30 AM EDT - 22 days ago

Barinthus Biotherapeutics Earnings release: Q1 2026


Barinthus Biotherapeutics Quarterly report: Q1 2026

Apr 30, 2026, 7:30 AM EDT - 22 days ago

Barinthus Biotherapeutics Quarterly report: Q1 2026


Barinthus Biotherapeutics Slides: Corporate presentation

Apr 30, 2026, 7:00 AM EDT - 22 days ago

Barinthus Biotherapeutics Slides: Corporate presentation


Barinthus Biotherapeutics Earnings release: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Barinthus Biotherapeutics Earnings release: Q4 2025


Barinthus Biotherapeutics Annual report: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Barinthus Biotherapeutics Annual report: Q4 2025


Barinthus Biotherapeutics Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Barinthus Biotherapeutics Slides: Corporate presentation


Barinthus Biotherapeutics Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

Barinthus Biotherapeutics Earnings release: Q3 2025


Barinthus Biotherapeutics Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

Barinthus Biotherapeutics Quarterly report: Q3 2025


Barinthus Bio, Clywedog enter definitive merger agreement

2025-09-30T12:26:41.000Z - 8 months ago

Barinthus Bio, Clywedog enter definitive merger agreement


Barinthus Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Barinthus Biotherapeutics Earnings release: Q2 2025


Barinthus Biotherapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Barinthus Biotherapeutics Quarterly report: Q2 2025


Barinthus Biotherapeutics sees cash runway into 2027

2025-08-07T12:06:13.000Z - 10 months ago

Barinthus Biotherapeutics sees cash runway into 2027


Barinthus Biotherapeutics Earnings release: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Barinthus Biotherapeutics Earnings release: Q1 2025


Barinthus Biotherapeutics Quarterly report: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Barinthus Biotherapeutics Quarterly report: Q1 2025


Barinthus Biotherapeutics Slides: Corporate Presentation

May 6, 2025, 7:20 AM EDT - 1 year ago

Barinthus Biotherapeutics Slides: Corporate Presentation


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics sees cash runway into 2027

2025-03-20T11:30:09.000Z - 1 year ago

Barinthus Biotherapeutics sees cash runway into 2027


Barinthus Biotherapeutics Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Barinthus Biotherapeutics Earnings release: Q4 2024


Barinthus Biotherapeutics Annual report: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Barinthus Biotherapeutics Annual report: Q4 2024


Barinthus Biotherapeutics Slides: Corporate Presentation

Jan 9, 2025, 7:00 PM EST - 1 year ago

Barinthus Biotherapeutics Slides: Corporate Presentation


Barinthus Biotherapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Barinthus Biotherapeutics Quarterly report: Q3 2024


Barinthus Biotherapeutics Earnings release: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Barinthus Biotherapeutics Earnings release: Q3 2024


Barinthus Biotherapeutics Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Barinthus Biotherapeutics Quarterly report: Q2 2024


Barinthus Biotherapeutics Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Barinthus Biotherapeutics Earnings release: Q2 2024


Barinthus Biotherapeutics Quarterly report: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Barinthus Biotherapeutics Quarterly report: Q1 2024


Barinthus Biotherapeutics Earnings release: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Barinthus Biotherapeutics Earnings release: Q1 2024


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Annual report: Q4 2023

Mar 19, 2024, 7:00 PM EDT - 2 years ago

Barinthus Biotherapeutics Annual report: Q4 2023


Barinthus Biotherapeutics Earnings release: Q4 2023

Mar 19, 2024, 7:00 PM EDT - 2 years ago

Barinthus Biotherapeutics Earnings release: Q4 2023


Barinthus Biotherapeutics Quarterly report: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Barinthus Biotherapeutics Quarterly report: Q3 2023


Barinthus Biotherapeutics Earnings release: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Barinthus Biotherapeutics Earnings release: Q3 2023


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Oct 5, 2023, 8:00 AM EDT - 2 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Sep 25, 2023, 8:00 AM EDT - 2 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Transcript: Status Update

Sep 20, 2023, 2:00 PM EDT - 2 years ago

Barinthus Biotherapeutics Transcript: Status Update


Barinthus Biotherapeutics Quarterly report: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Barinthus Biotherapeutics Quarterly report: Q2 2023


Barinthus Biotherapeutics Earnings release: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Barinthus Biotherapeutics Earnings release: Q2 2023


Barinthus Biotherapeutics Quarterly report: Q1 2023

May 11, 2023, 6:00 PM EDT - 3 years ago

Barinthus Biotherapeutics Quarterly report: Q1 2023


Barinthus Biotherapeutics Earnings release: Q1 2023

May 11, 2023, 6:00 PM EDT - 3 years ago

Barinthus Biotherapeutics Earnings release: Q1 2023


Barinthus Biotherapeutics Proxy statement: Proxy Filing

Mar 29, 2023, 8:00 AM EDT - 3 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Annual report: Q4 2022

Mar 23, 2023, 7:00 PM EDT - 3 years ago

Barinthus Biotherapeutics Annual report: Q4 2022


Barinthus Biotherapeutics Earnings release: Q4 2022

Mar 23, 2023, 7:00 PM EDT - 3 years ago

Barinthus Biotherapeutics Earnings release: Q4 2022


Barinthus Biotherapeutics Transcript: Status Update

Nov 28, 2022, 4:30 PM EST - 3 years ago

Barinthus Biotherapeutics Transcript: Status Update


Barinthus Biotherapeutics Quarterly report: Q3 2022

Nov 9, 2022, 6:00 PM EST - 3 years ago

Barinthus Biotherapeutics Quarterly report: Q3 2022


Barinthus Biotherapeutics Earnings release: Q3 2022

Nov 9, 2022, 6:00 PM EST - 3 years ago

Barinthus Biotherapeutics Earnings release: Q3 2022


Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 20, 2022, 4:30 PM EDT - 3 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer


Barinthus Biotherapeutics Quarterly report: Q2 2022

Aug 8, 2022, 6:00 PM EDT - 4 years ago

Barinthus Biotherapeutics Quarterly report: Q2 2022


Barinthus Biotherapeutics Earnings release: Q2 2022

Aug 8, 2022, 6:00 PM EDT - 4 years ago

Barinthus Biotherapeutics Earnings release: Q2 2022


Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 4:15 PM EDT - 4 years ago

Vaccitech to Present at the Jefferies Healthcare Conference


Barinthus Biotherapeutics Proxy statement: Proxy Filing

May 13, 2022, 8:00 AM EDT - 4 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Quarterly report: Q1 2022

May 10, 2022, 6:00 PM EDT - 4 years ago

Barinthus Biotherapeutics Quarterly report: Q1 2022


Barinthus Biotherapeutics Earnings release: Q1 2022

May 10, 2022, 6:00 PM EDT - 4 years ago

Barinthus Biotherapeutics Earnings release: Q1 2022


Barinthus Biotherapeutics Proxy statement: Proxy Filing

May 2, 2022, 8:00 AM EDT - 4 years ago

Barinthus Biotherapeutics Proxy statement: Proxy Filing


Barinthus Biotherapeutics Annual report: Q4 2021

Mar 24, 2022, 7:00 PM EDT - 4 years ago

Barinthus Biotherapeutics Annual report: Q4 2021


Barinthus Biotherapeutics Earnings release: Q4 2021

Mar 24, 2022, 7:00 PM EDT - 4 years ago

Barinthus Biotherapeutics Earnings release: Q4 2021


Barinthus Biotherapeutics Transcript: Status Update

Jan 25, 2022, 8:30 AM EST - 4 years ago

Barinthus Biotherapeutics Transcript: Status Update


Barinthus Biotherapeutics Slides: Status Update

Jan 25, 2022, 8:30 AM EST - 4 years ago

Barinthus Biotherapeutics Slides: Status Update


focafoca99
focafoca99 May. 21 at 10:15 AM
$BRNS secured shareholder approval of its Scheme of Arrangement after a 99.98% vote in favor.
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 1:40 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 13 at 10:10 PM
$BRNS Brilliant piece that captures BRNS's situation perfectly. So if you want to update your understanding of BRNS or get to know BRNS better, this is essential reading. https://everyticker.com/quote/BRNS/analysis/barinthus-bio-s-0-67-survival-bet-merger-lifeline-meets-celiac-catalyst-nasdaq-brns
0 · Reply
xElysian
xElysian May. 9 at 6:17 AM
$BRNS Barinthus is currently in the process of merging with Clywedog Therapeutics, a move expected to close in mid-2026.
0 · Reply
PenkeInvesting
PenkeInvesting May. 4 at 11:05 PM
Fundamental analysis of $BRNS (Barinthus Biotherapeutics plc.) based on financial data and reported results. #BRNS
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 16 at 3:30 PM
$VTGN Any good CEO already has a contingency plan in place in case data is not good. Most likely they are already in talks for some sort of strategic alt deal if the data is meh. $RLYB did it, $CYCN did it, $BRNS did it, $NEUP did it, all behind the scenes while waiting on data and continuing business as usual. With 60m cash on hand Dec 31, and likely 45m+ on hand today we are trading at over 1/2 cash value. Any binary announcement likely has limited downside and loads of upside. Again, no matter the result here I still think it is a asymmetrical risk/reward situation. Risk -30% to possibly gain 100%+ Do your own DD of course but I've loaded up the boat. Options: A). Data is good, stock pumps B). Data is bad, announce strat alt review , stock rebounds to near current levels C). Reverse merger deal out of nowhere, stock explodes based on cash position. Look at $RLYB $CYCN $BRNS etc. All of them happened out of nowhere.
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 13 at 9:10 PM
$BRNS RSI: 41.43, MACD: -0.0172 Vol: 0.05, MA20: 0.59, MA50: 0.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 13 at 8:14 PM
$PCSA I still maintain this is less about data and more likely a RM play, whether it be a crypto treasury RM w/ Dreyfus or some other company. I think the data continually being delayed is very telling that the company is not planning on continuing on their own. Just my opinion. $BRNS $VYNE and $RLYB all are recent examples of companies who had upcoming data but all ended up doing RM's instead.
2 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 7 at 6:19 PM
$NEUP Both the $GLTO and $BRNS CEO's sent me similiar responses and then the deal was announced with 10 days of each of them...so assuming timing is always iffy. But this is a good, solid response. Thanks for sharing.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 20 at 5:00 AM
$BRNS Q4 '25 Earnings Results & Recap Barinthus Biotherapeutics PLC expects to incur net operating losses for at least the next several years as it advances product candidates and anticipates its existing cash, cash equivalents, and restricted cash will fund operations for at least 12 months.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 10:13 AM
$BRNS Current Stock Price: $0.58
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 6:29 PM
$BRNS RSI: 32.17, MACD: -0.0353 Vol: 0.06, MA20: 0.66, MA50: 0.70 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
floatchad
floatchad Feb. 20 at 4:24 PM
$BRNS Burns & McDonnell microcap exposure. Fundamentals are unclear. Liquidity risk dominates.
0 · Reply
johnnygogogo
johnnygogogo Feb. 12 at 11:29 PM
$BRNS hello? Anyone? Bueller?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 7:53 PM
$BRNS RSI: 48.09, MACD: -0.0066 Vol: 0.02, MA20: 0.73, MA50: 0.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 5:41 PM
0 · Reply
DeltaDomain
DeltaDomain Dec. 25 at 4:12 PM
$BRNS Macro forces may influence direction, yet internal execution remains the decisive factor. Reliability of results matters more than short bursts of momentum. Visible traction across segments would strengthen the thesis. Over time, credibility will hinge on repeatable performance.
0 · Reply
Zaga64
Zaga64 Dec. 19 at 6:40 PM
$BRNS I'm trying to buy but I'm getting this message. Your order is not eligible for electronic entry. Please call a Charles Schwab representative at (800) 435-4000 for assistance with this trade. (AC4205)
0 · Reply
prismmarketview
prismmarketview Dec. 10 at 8:11 PM
Barinthus $BRNS reports positive Phase 1 results for VTP-1000 in celiac disease prismmarketview.com/barinth......
0 · Reply
DARKP00L
DARKP00L Dec. 10 at 1:33 PM
$BRNS 08:02 on Dec. 10 2025 Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease #tradeideas
0 · Reply